NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma, Inc. (NVCT) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | D+ (1.8) | C+ (2.8) | B (3.3) | C+ (2.6) | C+ (2.6) |
| 2026-11-06 | C+ (2.5) | D+ (1.8) | C- (1.9) | B (3.4) | C+ (2.7) | C (2.5) |
| 2026-10-30 | C+ (2.5) | D+ (1.8) | C (2.4) | B (3.4) | C+ (2.7) | C+ (2.6) |
| 2026-10-23 | C+ (2.5) | C- (1.9) | C (2.4) | B (3.4) | C+ (2.6) | C+ (2.6) |
| 2026-10-16 | C+ (2.5) | D+ (1.8) | C (2.4) | B (3.4) | C+ (2.6) | C+ (2.6) |